Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

The underlying etiology of infantile spasms (West syndrome): Information from the International Collaborative Infantile Spasms Study (ICISS).

Osborne JP, Edwards SW, Dietrich Alber F, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay M, Mallick A, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, O'Callaghan FJK; participating investigators.

Epilepsia. 2019 Sep;60(9):1861-1869. doi: 10.1111/epi.16305. Epub 2019 Aug 16.

PMID:
31418851
2.

The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients.

Rodsaward P, Chottawornsak N, Suwanchote S, Rachayon M, Deekajorndech T, Wright HL, Edwards SW, Beresford MW, Rerknimitr P, Chiewchengchol D.

Asian Pac J Allergy Immunol. 2019 Apr 23. doi: 10.12932/AP-211218-0465. [Epub ahead of print]

3.

Human neutrophils activated via TLR8 promote Th17 polarization through IL-23.

Tamassia N, Arruda-Silva F, Wright HL, Moots RJ, Gardiman E, Bianchetto-Aguilera F, Gasperini S, Capone M, Maggi L, Annunziato F, Edwards SW, Cassatella MA.

J Leukoc Biol. 2019 Jun;105(6):1155-1165. doi: 10.1002/JLB.MA0818-308R. Epub 2019 Feb 28.

PMID:
30817049
4.

A robust intracellular metabolite extraction protocol for human neutrophil metabolic profiling.

Chokesuwattanaskul S, Phelan MM, Edwards SW, Wright HL.

PLoS One. 2018 Dec 20;13(12):e0209270. doi: 10.1371/journal.pone.0209270. eCollection 2018.

5.

High macrophage activities are associated with advanced periductal fibrosis in chronic Opisthorchis viverrini infection.

Salao K, Watakulsin K, Mairiang E, Suttiprapa S, Tangkawattana S, Edwards SW, Sripa B.

Parasite Immunol. 2019 Jan;41(1):e12603. doi: 10.1111/pim.12603. Epub 2018 Dec 3.

PMID:
30449026
6.

Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial.

O'Callaghan FJK, Edwards SW, Alber FD, Cortina Borja M, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay MT, Mallick AA, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, Osborne JP; International Collaborative Infantile Spasms Study (ICISS) investigators.

Lancet Child Adolesc Health. 2018 Oct;2(10):715-725. doi: 10.1016/S2352-4642(18)30244-X. Epub 2018 Aug 29.

PMID:
30236380
7.

Opisthorchiasis-Induced Cholangiocarcinoma: How Innate Immunity May Cause Cancer.

Edwards SW, Spofford EM, Price C, Wright HL, Salao K, Suttiprapa S, Sripa B.

Adv Parasitol. 2018;101:149-176. doi: 10.1016/bs.apar.2018.05.006. Epub 2018 May 29. Review.

PMID:
29907253
8.

The Adverse Outcome Pathway: A Multifaceted Framework Supporting 21st Century Toxicology.

Ankley GT, Edwards SW.

Curr Opin Toxicol. 2018 Jun 1;9:1-7. doi: 10.1016/j.cotox.2018.03.004.

9.

Differentiating Pathway-Specific From Nonspecific Effects in High-Throughput Toxicity Data: A Foundation for Prioritizing Adverse Outcome Pathway Development.

Fay KA, Villeneuve DL, Swintek J, Edwards SW, Nelms MD, Blackwell BR, Ankley GT.

Toxicol Sci. 2018 Jun 1;163(2):500-515. doi: 10.1093/toxsci/kfy049.

10.

Anti-neutrophil cytoplasmic antibodies and their clinical significance.

Suwanchote S, Rachayon M, Rodsaward P, Wongpiyabovorn J, Deekajorndech T, Wright HL, Edwards SW, Beresford MW, Rerknimitr P, Chiewchengchol D.

Clin Rheumatol. 2018 Apr;37(4):875-884. doi: 10.1007/s10067-018-4062-x. Epub 2018 Mar 10. Review.

PMID:
29525845
11.

AOP-DB: A database resource for the exploration of Adverse Outcome Pathways through integrated association networks.

Pittman ME, Edwards SW, Ives C, Mortensen HM.

Toxicol Appl Pharmacol. 2018 Mar 15;343:71-83. doi: 10.1016/j.taap.2018.02.006. Epub 2018 Feb 14.

12.

The CDK inhibitor purvalanol A induces neutrophil apoptosis and increases the turnover rate of Mcl-1: potential role of p38-MAPK in regulation of Mcl-1 turnover.

Phoomvuthisarn P, Cross A, Glennon-Alty L, Wright HL, Edwards SW.

Clin Exp Immunol. 2018 May;192(2):171-180. doi: 10.1111/cei.13107. Epub 2018 Mar 9.

13.
14.

Oral Ulcers in Juvenile-Onset Systemic Lupus Erythematosus: A Review of the Literature.

Rodsaward P, Prueksrisakul T, Deekajorndech T, Edwards SW, Beresford MW, Chiewchengchol D.

Am J Clin Dermatol. 2017 Dec;18(6):755-762. doi: 10.1007/s40257-017-0286-9. Review.

15.

Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.

O'Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay M, Mallick AA, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, Osborne JP; participating investigators.

Lancet Neurol. 2017 Jan;16(1):33-42. doi: 10.1016/S1474-4422(16)30294-0. Epub 2016 Nov 10.

PMID:
27838190
16.

The Next Generation of Risk Assessment Multi-Year Study-Highlights of Findings, Applications to Risk Assessment, and Future Directions.

Cote I, Andersen ME, Ankley GT, Barone S, Birnbaum LS, Boekelheide K, Bois FY, Burgoon LD, Chiu WA, Crawford-Brown D, Crofton KM, DeVito M, Devlin RB, Edwards SW, Guyton KZ, Hattis D, Judson RS, Knight D, Krewski D, Lambert J, Maull EA, Mendrick D, Paoli GM, Patel CJ, Perkins EJ, Poje G, Portier CJ, Rusyn I, Schulte PA, Simeonov A, Smith MT, Thayer KA, Thomas RS, Thomas R, Tice RR, Vandenberg JJ, Villeneuve DL, Wesselkamper S, Whelan M, Whittaker C, White R, Xia M, Yauk C, Zeise L, Zhao J, DeWoskin RS.

Environ Health Perspect. 2016 Nov;124(11):1671-1682. Epub 2016 Apr 19. Review.

17.

Wolbachia endosymbionts induce neutrophil extracellular trap formation in human onchocerciasis.

Tamarozzi F, Turner JD, Pionnier N, Midgley A, Guimaraes AF, Johnston KL, Edwards SW, Taylor MJ.

Sci Rep. 2016 Oct 18;6:35559. doi: 10.1038/srep35559.

18.

Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis.

Wright HL, Cox T, Moots RJ, Edwards SW.

J Leukoc Biol. 2017 Mar;101(3):785-795. doi: 10.1189/jlb.5A0616-258R. Epub 2016 Oct 12.

PMID:
27733572
19.

Editor's Highlight: Negative Predictors of Carcinogenicity for Environmental Chemicals.

Hill T 3rd, Nelms MD, Edwards SW, Martin M, Judson R, Corton JC, Wood CE.

Toxicol Sci. 2017 Jan;155(1):157-169. doi: 10.1093/toxsci/kfw195. Epub 2016 Sep 27.

PMID:
27679563
20.

Low-density granulocytes: functionally distinct, immature neutrophils in rheumatoid arthritis with altered properties and defective TNF signalling.

Wright HL, Makki FA, Moots RJ, Edwards SW.

J Leukoc Biol. 2017 Feb;101(2):599-611. doi: 10.1189/jlb.5A0116-022R. Epub 2016 Sep 6.

PMID:
27601627
21.

Expanding on Successful Concepts, Models, and Organization.

Teeguarden JG, Tan YM, Edwards SW, Leonard JA, Anderson KA, Corley RA, Kile ML, L Massey Simonich S, Stone D, Tanguay RL, Waters KM, Harper SL, Williams DE.

Environ Sci Technol. 2016 Sep 6;50(17):8921-2. doi: 10.1021/acs.est.6b03027. Epub 2016 Aug 10. No abstract available.

PMID:
27509267
22.

An integrative data mining approach to identifying adverse outcome pathway signatures.

Oki NO, Edwards SW.

Toxicology. 2016 Mar 28;350-352:49-61. doi: 10.1016/j.tox.2016.04.004. Epub 2016 Apr 20.

PMID:
27108252
23.

Differential changes in gene expression in human neutrophils following TNF-α stimulation: Up-regulation of anti-apoptotic proteins and down-regulation of proteins involved in death receptor signaling.

Chiewchengchol D, Wright HL, Thomas HB, Lam CW, Roberts KJ, Hirankarn N, Beresford MW, Moots RJ, Edwards SW.

Immun Inflamm Dis. 2015 Dec 2;4(1):35-44. doi: 10.1002/iid3.90. eCollection 2016 Mar.

24.

Human neutrophils in auto-immunity.

Thieblemont N, Wright HL, Edwards SW, Witko-Sarsat V.

Semin Immunol. 2016 Apr;28(2):159-73. doi: 10.1016/j.smim.2016.03.004. Epub 2016 Mar 29. Review.

PMID:
27036091
25.

Integrating Publicly Available Data to Generate Computationally Predicted Adverse Outcome Pathways for Fatty Liver.

Bell SM, Angrish MM, Wood CE, Edwards SW.

Toxicol Sci. 2016 Apr;150(2):510-20. doi: 10.1093/toxsci/kfw017. Epub 2016 Feb 19.

PMID:
26895641
26.

Accelerating Adverse Outcome Pathway Development Using Publicly Available Data Sources.

Oki NO, Nelms MD, Bell SM, Mortensen HM, Edwards SW.

Curr Environ Health Rep. 2016 Mar;3(1):53-63. doi: 10.1007/s40572-016-0079-y. Review.

PMID:
26809562
27.

Completing the Link between Exposure Science and Toxicology for Improved Environmental Health Decision Making: The Aggregate Exposure Pathway Framework.

Teeguarden JG, Tan YM, Edwards SW, Leonard JA, Anderson KA, Corley RA, Kile ML, Simonich SM, Stone D, Tanguay RL, Waters KM, Harper SL, Williams DE.

Environ Sci Technol. 2016 May 3;50(9):4579-86. doi: 10.1021/acs.est.5b05311. Epub 2016 Feb 10.

28.

Adverse Outcome Pathways-Organizing Toxicological Information to Improve Decision Making.

Edwards SW, Tan YM, Villeneuve DL, Meek ME, McQueen CA.

J Pharmacol Exp Ther. 2016 Jan;356(1):170-81. doi: 10.1124/jpet.115.228239. Epub 2015 Nov 4. Review.

PMID:
26537250
29.

Whose Gene Is It Anyway? The Effect of Preparation Purity on Neutrophil Transcriptome Studies.

Thomas HB, Moots RJ, Edwards SW, Wright HL.

PLoS One. 2015 Sep 24;10(9):e0138982. doi: 10.1371/journal.pone.0138982. eCollection 2015.

30.

Systems Biology and Biomarkers of Early Effects for Occupational Exposure Limit Setting.

DeBord DG, Burgoon L, Edwards SW, Haber LT, Kanitz MH, Kuempel E, Thomas RS, Yucesoy B.

J Occup Environ Hyg. 2015;12 Suppl 1:S41-54. doi: 10.1080/15459624.2015.1060324.

31.

A Workflow to Investigate Exposure and Pharmacokinetic Influences on High-Throughput in Vitro Chemical Screening Based on Adverse Outcome Pathways.

Phillips MB, Leonard JA, Grulke CM, Chang DT, Edwards SW, Brooks R, Goldsmith MR, El-Masri H, Tan YM.

Environ Health Perspect. 2016 Jan;124(1):53-60. doi: 10.1289/ehp.1409450. Epub 2015 May 15.

32.

Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.

Becker RA, Ankley GT, Edwards SW, Kennedy SW, Linkov I, Meek B, Sachana M, Segner H, Van Der Burg B, Villeneuve DL, Watanabe H, Barton-Maclaren TS.

Regul Toxicol Pharmacol. 2015 Aug;72(3):514-37. doi: 10.1016/j.yrtph.2015.04.004. Epub 2015 Apr 8.

33.

Uses of NHANES Biomarker Data for Chemical Risk Assessment: Trends, Challenges, and Opportunities.

Sobus JR, DeWoskin RS, Tan YM, Pleil JD, Phillips MB, George BJ, Christensen K, Schreinemachers DM, Williams MA, Hubal EA, Edwards SW.

Environ Health Perspect. 2015 Oct;123(10):919-27. doi: 10.1289/ehp.1409177. Epub 2015 Apr 10. Review.

34.

Identification and Prioritization of Relationships between Environmental Stressors and Adverse Human Health Impacts.

Bell SM, Edwards SW.

Environ Health Perspect. 2015 Nov;123(11):1193-9. doi: 10.1289/ehp.1409138. Epub 2015 Apr 10.

35.

Killing of Escherichia coli by Crohn's Disease Monocyte-derived Macrophages and Its Enhancement by Hydroxychloroquine and Vitamin D.

Flanagan PK, Chiewchengchol D, Wright HL, Edwards SW, Alswied A, Satsangi J, Subramanian S, Rhodes JM, Campbell BJ.

Inflamm Bowel Dis. 2015 Jul;21(7):1499-510. doi: 10.1097/MIB.0000000000000387.

36.

Cutaneous immunopathology of long-standing complex regional pain syndrome.

Osborne S, Farrell J, Dearman RJ, MacIver K, Naisbitt DJ, Moots RJ, Edwards SW, Goebel A.

Eur J Pain. 2015 Nov;19(10):1516-26. doi: 10.1002/ejp.685. Epub 2015 Feb 25.

PMID:
25728589
37.

Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab.

Wright HL, Mewar D, Bucknall RC, Edwards SW, Moots RJ.

Rheumatology (Oxford). 2015 Apr;54(4):743-4. doi: 10.1093/rheumatology/keu488. Epub 2015 Feb 8. No abstract available.

PMID:
25667432
38.

Data-driven asthma endotypes defined from blood biomarker and gene expression data.

George BJ, Reif DM, Gallagher JE, Williams-DeVane CR, Heidenfelder BL, Hudgens EE, Jones W, Neas L, Hubal EA, Edwards SW.

PLoS One. 2015 Feb 2;10(2):e0117445. doi: 10.1371/journal.pone.0117445. eCollection 2015.

39.

Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature.

Chiewchengchol D, Murphy R, Edwards SW, Beresford MW.

Pediatr Rheumatol Online J. 2015 Jan 5;13:1. doi: 10.1186/1546-0096-13-1. eCollection 2015. Review.

40.

Heparin derivatives for the targeting of multiple activities in the inflammatory response.

Veraldi N, Hughes AJ, Rudd TR, Thomas HB, Edwards SW, Hadfield L, Skidmore MA, Siligardi G, Cosentino C, Shute JK, Naggi A, Yates EA.

Carbohydr Polym. 2015 Mar 6;117:400-7. doi: 10.1016/j.carbpol.2014.09.079. Epub 2014 Oct 7.

PMID:
25498652
41.

A lack of confirmation with alternative assays questions the validity of IL-17A expression in human neutrophils using immunohistochemistry.

Tamarozzi F, Wright HL, Thomas HB, Edwards SW, Taylor MJ.

Immunol Lett. 2014 Dec;162(2 Pt B):194-8. doi: 10.1016/j.imlet.2014.10.025. Epub 2014 Oct 28.

42.

The protective effect of GM-CSF on serum-induced neutrophil apoptosis in juvenile systemic lupus erythematosus patients.

Chiewchengchol D, Midgley A, Sodsai P, Deekajorndech T, Hirankarn N, Beresford MW, Edwards SW.

Clin Rheumatol. 2015 Jan;34(1):85-91. doi: 10.1007/s10067-014-2800-2. Epub 2014 Oct 26.

PMID:
25344776
43.

Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA).

Tollefsen KE, Scholz S, Cronin MT, Edwards SW, de Knecht J, Crofton K, Garcia-Reyero N, Hartung T, Worth A, Patlewicz G.

Regul Toxicol Pharmacol. 2014 Dec;70(3):629-40. doi: 10.1016/j.yrtph.2014.09.009. Epub 2014 Sep 27.

44.

Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy.

Wright HL, Thomas HB, Moots RJ, Edwards SW.

Rheumatology (Oxford). 2015 Jan;54(1):188-93. doi: 10.1093/rheumatology/keu299. Epub 2014 Aug 13.

PMID:
25125592
45.

The multifactorial role of neutrophils in rheumatoid arthritis.

Wright HL, Moots RJ, Edwards SW.

Nat Rev Rheumatol. 2014 Oct;10(10):593-601. doi: 10.1038/nrrheum.2014.80. Epub 2014 Jun 10. Review.

PMID:
24914698
46.

Human filarial Wolbachia lipopeptide directly activates human neutrophils in vitro.

Tamarozzi F, Wright HL, Johnston KL, Edwards SW, Turner JD, Taylor MJ.

Parasite Immunol. 2014 Oct;36(10):494-502. doi: 10.1111/pim.12122.

47.

Mucocutaneous manifestations in a UK national cohort of juvenile-onset systemic lupus erythematosus patients.

Chiewchengchol D, Murphy R, Morgan T, Edwards SW, Leone V, Friswell M, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, Gardner-Medwin J, Wilkinson N, Riley P, Tizard J, Armon K, Sinha MD, Ioannou Y, Mann R, Bailey K, Davidson J, Baildam EM, Pain CE, Cleary G, McCann LJ, Beresford MW; UK JSLE Study Group.

Rheumatology (Oxford). 2014 Aug;53(8):1504-12. doi: 10.1093/rheumatology/keu137. Epub 2014 Mar 31.

PMID:
24692572
48.

Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo.

Wright HL, Cross AL, Edwards SW, Moots RJ.

Rheumatology (Oxford). 2014 Jul;53(7):1321-31. doi: 10.1093/rheumatology/keu035. Epub 2014 Mar 7.

PMID:
24609058
49.

Decision tree-based method for integrating gene expression, demographic, and clinical data to determine disease endotypes.

Williams-DeVane CR, Reif DM, Hubal EC, Bushel PR, Hudgens EE, Gallagher JE, Edwards SW.

BMC Syst Biol. 2013 Nov 4;7:119. doi: 10.1186/1752-0509-7-119.

50.

Inhibition of pre-B cell colony-enhancing factor (PBEF/NAMPT/visfatin) decreases the ability of human neutrophils to generate reactive oxidants but does not impair bacterial killing.

Roberts KJ, Cross A, Vasieva O, Moots RJ, Edwards SW.

J Leukoc Biol. 2013 Sep;94(3):481-92. doi: 10.1189/jlb.1012527. Epub 2013 Jun 26.

PMID:
23804809

Supplemental Content

Loading ...
Support Center